Pressure in Medical Technology

FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent

EAST HANOVER, N.J., July 21 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved Tekturna HCT((R)) (aliskiren and hydrochlorothiazide) tablets as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals. Tek...

Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results

First-Ever Trial to Evaluate Whether Olmesartan Medoxomil Prevents Onset of Early Kidney Disease in Type 2 Diabetes Patients SAN FRANCISCO, May 8 /PRNewswire/ -- Blinded one-year blood pressure (BP) reduction data from the ongoing landmark study ROADMAP ( R andomized O lmesartan A nd D ...

New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure

PARSIPPANY, N.J., May 8 /PRNewswire/ -- Daiichi Sankyo, Inc. announced today that new data presented at the American Society of Hypertension, Inc. (ASH) Annual Scientific Meeting and Exposition (ASH 2009) in San Francisco from the BeniSILVER study found that BENICAR (R) and BENICAR HCT (R) pro...

NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis

SOPHIA ANTIPOLIS, France, December 17 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced positive results of a pre-specified pooled analysis of 2,734 patients with osteoarthritis (OA) from the 301, 302 and 303 pivotal phase 3 studies for naproxcinod. Both doses of ...

Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results

SOPHIA ANTIPOLIS, France, November 24 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced that the third pivotal phase 3 study for naproxcinod in patients with OA of the hip showed a highly statistically significant result (p<0.001) on all three co-primary effica...

NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study

SOPHIA ANTIPOLIS, France, November 4 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced positive top-line results from a 118 patient Ambulatory Blood Pressure Monitoring (ABPM) trial (the 111 study), which compared the 24-hour blood pressure profile of escalating doses ...

NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect

PARIS, September 15 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced successful top-line results from the second phase 3 study for naproxcinod in 1020 patients with osteoarthritis of the knee (the 302 study). Both doses of naproxcinod (750 mg and 375 mg bid) met the t...

August 2008 Mayo Clinic Women's HealthSource Highlights Avoiding Blood Pressure Increase at Menopause, Healthful Benefits of Dark Chocolate and Scheduling a Colorectal Exam

ROCHESTER, Minn., Aug. 6 /PRNewswire-USNewswire/ -- Here are highlights from the August issue of Mayo Clinic Women's HealthSource. You may cite this publication as often as you wish. Mayo Clinic Women's HealthSource attribution is required. Reprinting is allowed for a fee. Include the followin...

NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients

SOPHIA ANTIPOLIS, France, July 22 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced it has successfully completed the enrollment of 417 osteoarthritis (OA) patients with controlled hypertension in two clinical pharmacology studies in the United States, in line with pre...

Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies

New research continues to reinforce the efficacy of RESPeRATE while highlighting interest in the device by the scientific community BERLIN and NEW YORK, June 16 /PRNewswire/ -- European Society of Hypertension -- Booth # 21, Hall 15.1 -- InterCure Ltd., a medical device company publicly t...

New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering

Data published in the Journal of the American Society of Hypertension demonstrate that early blockade of angiotensin II reversed vascular hypertrophy PARSIPPANY, N.J., June 16 /PRNewswire/ -- A new study published in the current Journal of the American Society of...

NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR

SOPHIA ANTIPOLIS, France, June 13 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced an additional analysis of the blood pressure data from the 301 phase 3 study, showing a statistically significant difference between naproxcinod and naproxen in terms of the mean chan...

Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes

Phase 3 data highlight sustained efficacy and benefits of early treatment with liraglutide versus glimepiride SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Data presented today at the 68th Scientific Sessions of the American Diabetes Association (ADA) demonstrated that once-d...

New Study Linking 'High Normal' Blood Pressure to Significant Cardiovascular Risk

- AtCor Medical's SphygmoCor system plays key role in discovery ITASCA, Ill. and SYDNEY, Australia, May 28 /PRNewswire-FirstCall/ -- A new study of more than 10,000 patients, conducted by the Universities of Cambridge and Cardiff in the United Kingdom using AtCor Medical Holdings Limited's...

New Pharma Business Model Increases Pressure on Staff Communicating Trial Data

CHAPEL HILL, N.C., May 23 /PRNewswire/ -- With increased FDA scrutiny around new medicines and heightened competition from generics in the pharmaceutical market, marketing teams and science staff have to be even more delicate when communicating clinical trial results of new drugs in developmen...

Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City

SOUTH EASTON, Mass., May 21 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO ) ("PBI") today announced that scientists from the New York University (NYU) School of Medicine, the Brooklyn Hospital Center, and the Harvard School of Public Health made presentations highlighting...

Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients

Single Molecule with Dual Mechanism May Offer Novel Approach to Blood Pressure Management NEW ORLEANS, May 16 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced today tha...

Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations

Blood pressure reductions demonstrated in Blacks, Hispanics/Latinos, People with Diabetes and Obese Individuals PARSIPPANY, N.J., May 15 /PRNewswire/ -- Daiichi Sankyo, Inc., announced today that data presented at the American Society of Hypertension's Twenty- Third Annual Scien...

Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges

Monitoring, medication continuance needed to reduce cardiovascular risks ROCHESTER, Minn., April 8, 2008 /PRNewswire-USNewswire/ -- Many men who receive microwave therapy for enlarged prostates experience significant surges in blood pressure that could raise their risk of a heart attack or...

Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report

UPPSALA, Sweden, and WILMINGTON, Mass., March 28 /PRNewswire/ -- Use of a low profile PressureWire yields a more accurate assessment of translesion pressure gradients when compared to catheter-derived pressure gradient (CPG) measurements, according to a paper published in the Journal of Interv...

Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health

SOUTH EASTON, Mass., March 19 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO ) ("PBI") today announced that researchers from the Company and the Harvard School of Public Health (HSPH) have unveiled a novel approach for the simultaneous extraction, isolation, and fractionat...

American Heart Association Journal Report: Reducing Kids' Salt Intake May Lower Soft Drink Consumption, Reducing Obesity, High Blood Pressure and Later Health Risks

DALLAS, Feb. 20 /PRNewswire-USNewswire/ --- Children who eat less salt drink fewer sugar-sweetened soft drinks and may significantly lower their risks for obesity, elevated blood pressure and later-in-life heart attack and stroke, researchers reported in the print and online issue of Hypertens...

High Blood Pressure May Heighten Effects of Alzheimer's Disease

CHICAGO, Nov. 28 /PRNewswire/ -- Having hypertension, or high blood pressure, reduces blood flow in the brains of adults with Alzheimer's disease, according to a new study presented today at the annual meeting of the Radiological Society of North America (RSNA). "While hypertension is not a ...

UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension

NEW YORK, Nov. 1 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ) today announced the results of a double-blind, randomized, placebo-controlled clinical trial, published in the November 2007 issue of the Journal of Clinical Hypertension, which demonstrated that nebivolol signi...

Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension

NEW YORK, Nov. 1 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ) today announced the results of a double-blind, randomized, placebo-controlled clinical trial, published in the November 2007 issue of the Journal of Clinical Hypertension, which demonstrated that nebivolol signi...

Microlife's Home Blood Pressure Monitors Proven Accurate Even for Critical Patients

As Widespread Use of Home Blood Pressure Monitoring Becomes Recommended and the Need for Accurate Devices Expands to Include Critical Patients, Microlife Manufactures the Only Home Blood Pressure Monitor with Proven Accuracy (Severe arterial-sclerosis in End Stage Renal Disease) DUNEDIN, F...

Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in Miami

MIAMI, Sept. 12 /PRNewswire-USNewswire/ -- The National Alliance for Hispanic Health (the Alliance) is launching a new national program called Hypertension ... Control is in your Hands (Presion alta ... El control esta en tus manos) with the goal of raising awareness of hypertension (high bloo...

Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension

NEW YORK, Sept. 4 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ) announced the results of a controlled clinical trial, published in the September 2007 issue of the Journal of Clinical Hypertension, which demonstrated that nebivolol, a selective beta 1-blocker with vasodilati...

New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure

AZTEC Trial First to Examine AZOR Using 24-Hour Ambulatory BP Measures PARSIPPANY, N.J., May 8 /PRNewswire/ -- Daiichi Sankyo, Inc. announced today that data presented at the American Society of Hypertension, Inc. (ASH) Twenty-Fourth Annual Scientific Meeting and Exposition (ASH 2009) in San ...

Tekturna, First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan

* New study results show more patients receiving both Tekturna and Diovan reached target blood pressure goal compared to those taking either agent alone EAST HANOVER, N.J., March 26, 2007 /PRNewswire/ -- Results from a new study have shown patients taking two Novartis cardiovascular medicines -- t...

Pivotal Phase III Findings With Investigational Drug Cleviprex (Clevidipine) Demonstrate Perioperative Blood Pressure Control In Cardiac Surgery

First Presentation of Comparative Data from ECLIPSE, Largest Safety Program of Intravenous Antihypertensive Agents NEW ORLEANS, March 27, 2007 /PRNewswire-FirstCall/ -- Favorable findings of the investigational drug Cleviprex(TM) (clevidipine) compared to current intravenous antihypertensive agent...

First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan

Unprecedented Evidence for the Effectiveness of Hypertension Treatment Valsartan in Preventing Cardiovascular Events in Japanese Patients TOKYO, April 26, 2007 /Xinhua-PRNewswire/ -- The clinical outcomes of the JIKEI HEART Study, the large-scale clinical trial headed by the Jikei University Schoo...

Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data

Nine out of 10 non-diabetic patients treated with Exforge achieved recommended blood pressure goals[1] Additional average decrease of 20 mmHg in systolic blood pressure observed in patients taking Exforge over reductions seen with previous monotherapy[1] Nearly 70% of those with high blood...

King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For 24-hour Blood Pressure Control

BRISTOL, Tenn.--(BUSINESS WIRE)--May 19, 2007 - King Pharmaceuticals, Inc. (NYSE:KG) reported today that data from its Phase III clinical trial evaluating Altace (ramipril) 20mg and the combination of ALTACE 20mg and hydrochlorothiazide (HCT) 25mg were presented this weekend at the American Society...

Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril

Comparison of BENICAR HCT 40/12.5 and 40/25 mg/day and Amlodipine + Benazepril 5/20 and 10/20 mg/day Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting PARSIPPANY, N.J., May 21, 2007 /PRNewswire/ -- New data presented today at the American Society of Hypertension...

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

...ve dose group. The mean increase in blood pressure from baseline at 3 months, using a last observatio...of patients in the 100 mg bid dose group had blood pressure medication adjusted or in some cases initiated dur...s. For those patients who had their dose of blood pressure medications adjusted or initiated, their blood...

Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma

... Tell your health care provider right away about any symptoms such as feeling tired or exhausted, weakness, nausea, vomiting, or symptoms of low blood pressure (such as dizziness or faintness). If you or your child is under stress, such as with surgery, after surgery, or trauma, you may need steroids by mouth...

July 2009 Mayo Clinic Women's HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals

...until the flow of energy slows or stops. Like healing touch, reiki can promote relaxation. One study suggests it may positively affect blood pressure and heart and respiration rates. Because of a lack of research, it's hard to say for certain that energy therapies are completely safe and w...

Results From Trials of DHA in Alzheimer's Disease and Age-Related Cognitive Decline

...rate in those taking DHA (change from baseline of -3.2 vs. -1 BPM, p<0.03) that was highly correlated with week 24 plasma levels (p<0.01). Blood pressure and body weight remained unchanged between groups. Plasma levels of Alzheimer's related proteins Abeta 1-40, 1-42 and hs-CRP were not significantly di...

ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients

... Tell your health care provider right away about any symptoms such as feeling tired or exhausted, weakness, nausea, vomiting, or symptoms of low blood pressure (such as dizziness or faintness). If you or your child is under stress, such as with surgery, after surgery, or trauma, you may need steroids by mouth...